SequelSEC

OptimizeRx Corp OPRX

Services-Business Services, NEC · CIK 0001448431 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$20.50M
Fiscal year ended 2026-06-30
Operating income
-$88.00K
Fiscal year ended 2026-06-30
Free cash flow
$8.58M
Fiscal year ended 2026-06-30

OptimizeRx Corp (OPRX) reported revenue of $20.50M and net income of -$703.00K for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from OptimizeRx Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Business Services, NEC.

Income

OptimizeRx Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$20.50M$19.84M$32.24M$26.07M$29.20M$21.93M$32.32M$21.31M$18.81M$19.69M
Cost of revenue$4.82M$4.91M$8.14M$8.55M$10.56M$8.58M$10.29M$7.86M$7.11M$7.49M
Gross profit$15.69M$14.93M$24.10M$17.52M$18.64M$13.34M$22.02M$13.45M$11.70M$12.20M
Operating income-$88.00K$396.00K$8.57M$2.05M$3.21M-$2.10M$3.63M-$8.56M-$3.75M-$5.03M
Net income-$703.00K-$495.00K$5.02M$779.00K$1.53M-$2.20M-$78.00K-$9.12M-$4.01M-$6.90M
Research & development$3.27M$3.40MUnavailableUnavailable$3.09M$3.25MUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 18.79Mshares 18.76MUnavailableshares 19.46Mshares 19.02Mshares 18.47MUnavailableshares 18.32Mshares 18.26Mshares 18.17M
Pretax income-$1.10M-$644.00K$7.47M$1.05M$1.73M-$3.27M$2.21M-$9.94M-$5.10M-$6.56M
Income tax expense-$393.00K-$149.00K$2.45M$270.00K$199.00K-$1.07M$2.29M-$817.00K-$1.09M$344.00K
Diluted EPS$-0.04$-0.03Unavailable$0.04$0.08$-0.12Unavailable$-0.50$-0.22$-0.38
Selling, general & administrative$9.23M$8.24MUnavailableUnavailable$9.77M$9.54MUnavailableUnavailableUnavailableUnavailable
General & administrative$3.70M$3.51MUnavailable$14.39M$3.91M$4.56MUnavailable$13.42M$14.38M$16.17M
Selling & marketing$5.53M$4.73MUnavailableUnavailable$5.86M$4.98MUnavailableUnavailableUnavailableUnavailable

Balance

OptimizeRx Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$24.10M$20.17M$23.36M$19.52M$16.58M$16.57M$13.38M$16.13MUnavailableUnavailable
Total assets$164.32M$167.26M$176.92M$170.32M$169.26M$167.77M$171.17M$165.20M$172.88M$176.37M
Current assets$54.15M$56.16M$64.72M$56.32M$54.08M$51.71M$53.97M$46.91M$45.97M$48.35M
Total liabilities$33.24M$37.65M$48.62M$48.06M$49.98M$51.50M$54.17M$50.73M$51.86M$53.83M
Current liabilities$9.71M$10.46M$21.26M$18.47M$21.06M$18.35M$18.65M$14.50M$14.96M$16.76M
Total equity incl. NCI$131.08M$129.61M$128.29M$122.26M$119.28M$116.27M$117.00M$114.46M$121.02M$122.54M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$24.80M$31.99M$37.75M$32.23M$33.51M$32.72M$38.21M$26.33M$24.52M$29.75M
Goodwill$70.87M$70.87M$70.87M$70.87M$70.87M$70.87M$70.87M$70.87M$78.36M$78.36M
Long-term debt$17.76M$21.34M$21.42M$24.80M$25.13M$29.19M$30.82M$33.28M$32.30M$32.41M
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

OptimizeRx Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$8.61M-$467.00K$7.09M$3.20M$4.56M$3.86M$198.00K$1.79M$782.00K$2.12M
Capital expenditures$35.00K$21.00K$11.00K$10.00K$10.00K$27.00K$17.00K$18.00K$45.00K$32.00K
Investing cash flow-$35.00K-$21.00K$206.00K-$10.00K-$44.00K-$84.00K-$120.00K-$92.00K-$85.00K-$153.00K
Financing cash flow-$4.66M-$2.71M-$3.45M-$258.00K-$4.50M-$587.00K-$2.82M-$532.00K-$915.00K-$640.00K
Net change in cash$3.93M-$3.20M$3.85M$2.93M$12.00K$3.19M-$2.75M$1.17M-$218.00K$1.32M
Stock-based compensation$2.21M$1.83M$1.96M$1.96M$1.49M$1.56M$2.94M$2.60M$2.90M$3.02M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.06M$1.06M$1.08M$1.08M$1.07M$1.09M$1.09M$1.10M$1.07M$1.07M

Derived

OptimizeRx Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$8.58M-$488.00K$7.08M$3.19M$4.55M$3.84M$181.00K$1.77M$737.00K$2.09M
Gross margin76.5%75.2%74.8%67.2%UnavailableUnavailable68.1%63.1%62.2%62.0%
Operating margin-0.4%2.0%26.6%7.9%11.0%-9.6%11.2%-40.2%-19.9%-25.5%
FCF margin41.8%-2.5%22.0%12.2%15.6%17.5%0.6%8.3%3.9%10.6%
SBC / revenue10.8%9.2%6.1%7.5%5.1%7.1%9.1%12.2%15.4%15.4%
Current ratio5.58x5.37x3.04x3.05x2.57x2.82x2.89x3.23x3.07x2.88x
Revenue YoY growth-29.8%-9.5%-0.2%22.3%55.2%11.4%13.9%30.5%36.1%51.4%
Net margin-3.4%Unavailable15.6%3.0%5.2%Unavailable-0.2%-42.8%UnavailableUnavailable
R&D / revenue16.0%17.1%UnavailableUnavailable10.6%14.8%UnavailableUnavailableUnavailableUnavailable
CapEx / revenue0.2%0.1%0.0%0.0%0.0%0.1%0.1%0.1%0.2%0.2%
Long-term debt / equity0.14xUnavailable0.17x0.20xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailable32.8%25.7%11.5%Unavailable103.5%UnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OPRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.